MicroRNA aberrations including that of miR-24-2 have been reported in various cancers. However, the target genes for miR-24-2 are yet to be identified and validated in invasive breast cancer and the triple-negative breast cancer (TNBC). Using in silico approaches and gene expression analyses, we identified and validated the target genes of miR-24-2 in invasive breast cancer, majority of which were TNBC. We studied the translational potential of these target genes using berberine in a TNBC cell line. Differentially expressed genes targeted by miR-24-2 were identified and analyzed for their survival effects using the The Cancer Genome Atlas-Breast Invasive Carcinoma (-BRCA) samples. Furthermore, we carried out protein–protein interaction, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, gene expression, and Kaplan-Meier survival analyses using common targets of miR-24-2 in invasive breast cancer/TNBC. We identified 11 biomarker candidate genes as crucial targets of miR-24-2. The survival of breast cancer patients was significantly associated with the low expressions of nine genes, including RACGAP1, KIAA1199, TIMM17A, LYRM7, IL1R1, SLC1A3, DTX4, L1CAM, and SAP30-like (SAP30L), and high expressions of two genes, SOD2 and HLA-DQB2. These in silico findings were validated by overexpressing miR-24-2 and assessing the expression pattern of these target genes in the TNBC MDA-MB-231 cells. miR-24-2 overexpression inhibited (by 20%; p < 0.001) cell proliferation and sensitized the anticancer effect of berberine. In all, this study reports on the novel target genes of miR-24-2 in invasive breast cancer/TNBC, and that miR-24-2 sensitizes MDA-MB-231 cells to berberine. These data lend evidence for the translational potentials of miR-24-2 for invasive breast cancer diagnostic and therapeutic innovation.
Get full access to this article
View all access options for this article.
References
1.
AghanooriM-R, Mirzaei B and TavallaeiM. MiRNA molecular profiles in human medical conditions: Connecting lung cancer and lung development phenomena. Asian Pac J Cancer Prev, 2014; 15(22):9557–9565; doi: 10.7314/apjcp.2014.15.22.9557
2.
Al-MahayriZN, PatrinosGP, AliBR. Toxicity and pharmacogenomic biomarkers in breast cancer chemotherapy. Front Pharmacol, 2020; 11(April):1–16; doi: 10.3389/fphar.2020.00445
3.
BerdozJ, TiercyJM, RolliniP, et al.Remarkable sequence conservation of the HLA-DQB2 locus (DX β) within the highly polymorphic DQ subregion of the human MHC. Immunogenetics, 1989; 29(4):241–248; doi: 10.1007/BF00717908
4.
ChandrashekarDS, KarthikeyanSK, KorlaPK, et al.UALCAN: An update to the integrated cancer data analysis platform. Neoplasia N Y N, 2022; 25:18–27; doi: 10.1016/j.neo.2022.01.001
5.
CaiJ, ChenJ, HuangL, et al.A TIMM17A regulatory network contributing to breast cancer. Front Genet, 2021; 12(August):1–15; doi: 10.3389/fgene.2021.658154
6.
ChenJ, GaoF, LiuN. L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer. Exp Ther Med, 2018; 15(3):2792–2797; doi: 10.3892/etm.2018.5747
7.
ChenL, ShiK, AndersenTL, et al.KIAA1199 is a secreted molecule that enhances osteoblastic stem cell migration and recruitment. Cell Death Dis, 2019; 10(2):1–13; doi: 10.1038/s41419-018-1202-9
8.
CuiJ, LiY, ZhuL, et al.NLRP4 negatively regulates type i interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat Immunol, 2012; 13(4):387–395; doi: 10.1038/ni.2239
9.
DagenaisM, Dupaul-ChicoineJ, DouglasT, et al.The interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis. Oncoimmunology, 2017; 6(3):1–11; doi: 10.1080/2162402X.2017.1287247
10.
FelicianoA, CastellviJ, Artero-CastroA, et al.MiR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9. PLoS One, 2013; 8(10):e76247; doi: 10.1371/journal.pone.0076247
11.
HaiJ, ZhuCQ, BandarchiB, et al.L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer. Clin Cancer Res, 2012; 18(7):1914–1924; doi: 10.1158/1078-0432.CCR-11-2893
12.
HeC, DanesJM, HartPC, et al.SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer. Proc Natl Acad Sci U S A, 2019; 116(47):23534–23541; doi: 10.1073/pnas.1902308116
13.
HiroseK, KawashimaT, IwamotoI, et al.MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody. J Biol Chem, 2001; 276(8):5821–5828; doi: 10.1074/jbc.M007252200
KohJ, KimMJ. Introduction of a new staging system of breast cancer for radiologists: An emphasis on the prognostic stage. Korean J Radiol, 2019; 20(1):69–82; doi: 10.3348/kjr.2018.0231
16.
KumarK, SabarwalA, SinghRP. Mancozeb selectively induces mitochondrial-mediated apoptosis in human gastric carcinoma cells through ROS generation. Mitochondrion, 2019; 48:1–10; doi: 10.1016/J.MITO.2018.06.003
17.
KumarM, JaiswalRK, PrasadR, et al.PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, P65 and ZEB1. Life Sci, 2021; 269; doi: 10.1016/j.lfs.2020.118994
18.
LeeRC, FeinbaumRL, AmbrosV. The C. Elegans heterochronic gene Lin-4 encodes small RNAs with antisense complementarity to Lin-14. Cell, 1993; 75(5):843–854; doi: 10.1016/0092-8674(93)90529-y
19.
LeeYS, DuttaA. MicroRNAs in cancer. Ann Rev Pathol Mech Dis, 2009; 4:199–227; doi: 10.1146/annurev.pathol.4.110807.092222
20.
LiLQ, YangY, ChenH, et al.MicroRNA-181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene. Cancer Biomark, 2016; 17(1):75–81; doi: 10.3233/CBM-160619
21.
LiY, GalileoDS. Soluble L1CAM promotes breast cancer cell adhesion and migration in vitro, but not invasion. Cancer Cell Int, 2010; 10:1–12; doi: 10.1186/1475-2867-10-34
22.
LiY, LiangY, SangY, et al.MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis, 2018; 9(1):1–12; doi: 10.1038/s41419-017-0030-7
23.
LiuJ, YanW, HanP, et al.The emerging role of KIAA1199 in cancer development and therapy. Biomed Pharmacother, 2021; 138(June):111507; doi: 10.1016/j.biopha.2021.111507
24.
LoSN, WangCW, ChenYS, et al.Berberine activates aryl hydrocarbon receptor but suppresses CYP1A1 induction through MiR-21-3p stimulation in MCF-7 breast cancer cells. Mol J Synth Chem Nat Prod Chem, 2017; 22(11); doi: 10.3390/MOLECULES22111847
25.
ManvatiS, MangalharaKC, KalaiarasanP, et al.MiR-24-2 regulates genes in survival pathway and demonstrates potential in reducing cellular viability in combination with docetaxel. Gene, 2015; 567(2):217–224; doi: 10.1016/j.gene.2015.05.003
26.
Milde-LangoschK, KarnT, MüllerV, et al.Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treat, 2013; 137(1):57–67; doi: 10.1007/s10549-012-2296-x
27.
RenK, ZhouD, WangM, et al.RACGAP1 modulates ECT2-dependent mitochondrial quality control to drive breast cancer metastasis. Exp Cell Res, 2021; 400(1):112493; doi: 10.1016/j.yexcr.2021.112493
28.
SalhabM, PataniN, JiangW, et al.High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer. Breast Cancer, 2012; 19(2):153–160; doi: 10.1007/s12282-010-0228-3
29.
SchauerIG, ZhangJ, XingZ, et al.Interleukin-1β promotes ovarian tumorigenesis through a P53/NF-ΚB-mediated inflammatory response in stromal fibroblasts. Neoplasia (United States), 2013; 15(4):409–420; doi: 10.1593/neo.121228
30.
SimpsonPT, Reis-FilhoJS, GaleT, et al.Molecular evolution of breast cancer. J Pathol, 2005; 205(2):248–254; doi: 10.1002/path.1691
31.
SrivastavaN, ManvatiS, SrivastavaA, et al.MiR-24-2 controls H2AFX expression regardless of gene copy number alteration and induces apoptosis by targeting antiapoptotic gene BCL-2: A potential for therapeutic intervention. Breast Cancer Res, 2011; 13(2):R39; doi: 10.1186/bcr2861
32.
SunJ, NagelR, ZaalEA, et al.SLC 1A3 contributes to L-asparaginase resistance in solid tumors. EMBO J, 2019; 38(21):1–16; doi: 10.15252/embj.2019102147
33.
SungH, FerlayJ, SiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71(3):209–249; doi: 10.3322/caac.21660
34.
SzklarczykD, KirschR, KoutrouliM, et al.The STRING database in 2023: Protein-protein association networks and function enrichment analyses for any sequenced genome of interest. Nucleic Acids Res, 2023; 51(D1):D638–D646; doi: 10.1093/nar/gkac1000
35.
TajanM, HockAK, BlagihJ, et al.A role for P53 in the adaptation to glutamine starvation through the expression of SLC1A3. Cell Metab, 2018; 28(5):721–736.e6; doi: 10.1016/j.cmet.2018.07.005
36.
TakJ, SabarwalA, ShyantiRK, et al.Berberine enhances posttranslational protein stability of p21/cip1 in breast cancer cells via down-regulation of Akt. Mol Cell Biochem, 2019; 458(1–2):49–59; doi: 10.1007/s11010-019-03529-4
37.
TerashimaM, FujitaY, TogashiY, et al.KIAA1199 interacts with glycogen phosphorylase kinase ß-subunit (PHKB) to promote glycogen breakdown and cancer cell survival. Oncotarget, 2014; 5(16):7040–7050; doi: 10.18632/oncotarget.2220
38.
TomczakK, CzerwińskaP, WiznerowiczM. The cancer genome atlas (TCGA): An immeasurable source of knowledge. Wspolczesna Onkol, 2015; 1A:A68–A77; doi: 10.5114/wo.2014.47136
39.
ViiriKM, HeinonenTY, MäkiM, et al.Phylogenetic analysis of the SAP30 family of transcriptional regulators reveals functional divergence in the domain that binds the nuclear matrix. BMC Evol Biol, 2009; 9(1):1–15; doi: 10.1186/1471-2148-9-149
40.
ViiriKM, KorkeamäkiH, KukkonenMK, et al.SAP30L interacts with members of the Sin3A corepressor complex and targets Sin3A to the nucleolus. Nucleic Acids Res, 2006; 34(11):3288–3298; doi: 10.1093/nar/gkl401
41.
WangJ, WangH, LiuA, et al.Lactate dehydrogenase a negatively regulated by MiRNAs promotes aerobic glycolysis and is increased in colorectal cancer. Oncotarget, 2015; 6(23):19456–19468; doi: 10.18632/oncotarget.3318
42.
WeigeltB, Reis-FilhoJS. Histological and molecular types of breast cancer: Is there a unifying taxonomy?. Nat Rev Clin Oncol, 2009; 6(12):718–730; doi: 10.1038/nrclinonc.2009.166
43.
WuG, XiaoG, YanY, et al.Bioinformatics analysis of the clinical significance of HLA class II in breast cancer. Medicine (United States), 2022; 101(40):E31071; doi: 10.1097/MD.0000000000031071
44.
YadavM, PradhanD, SinghRP. Integrated analysis and identification of nine-gene signature associated to oral squamous cell carcinoma pathogenesis. 3 Biotech, 2021; 11(5):1–15; doi: 10.1007/s13205-021-02737-4
45.
YersalO, BarutcaS. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol, 2014; 5(3):412–424; doi: 10.5306/wjco.v5.i3.412
46.
ZhangZ, FangT, LvY. A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer. Front Genet, 2022; 13(September):1–13; doi: 10.3389/fgene.2022.934830
47.
ZhuC, LiJ, HuaY, et al.Berberine inhibits the expression of SCT through MiR-214-3p stimulation in breast cancer cells. Evid-Based Complement Altern Med ECAM, 2020; 2020; doi: 10.1155/2020/2817147
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
